GSK (GSK) closed at $37.56 in the latest trading session, marking a +0.59% move from the prior day. The stock outperformed the S&P 500, which registered a daily gain of 0.43%.

We compare these trends to the stock’s performance during the 2008 recession. Notably, GSK stock has underperformed the broader market in each of the last three years. Returns for the stock were ...

GSK plc GSK will report its second-quarter earnings on Jul 31, before the opening bell. The Zacks Consensus Estimate for sales and earnings is pegged at $9.5 billion and $1.00 per share, respectively.

For new and old investors, taking full advantage of the stock market and investing with confidence are common ... which is more than double the S&P 500's performance over the same time frame. However, ...

Additionally, GSK has a PEG Ratio of 1.2 and a Price/Cash Flow ratio of 7.3X. Value investors should also note GSK's Price/Sales ratio of 2X. A company's earnings performance is important for ...

GSK shares fell after a Food and Drug Administration advisory committee voted against approval of the company's Blenrep drug, a setback for its bid to reintroduce the blood-cancer treatment in the U.S ...

GSK settles U.S. Zantac lawsuit, avoiding trial. Confidential settlements reinforce commitment to legal efficiency.

In addition to this performance, GSK plc (NYSE:GSK) has 5 new products in the pipeline for which it expects approval in 2025. The company has also raised its 2031 sales outlook to more than £40 ...

Additionally, GSK has a PEG Ratio of 1.3 and a Price/Cash Flow ratio of 6.8X. Value investors should also note GSK's Price/Sales ratio of 1.9X. A company's earnings performance is important for ...

A company's earnings performance is important for value investors as well. For fiscal 2025, five analysts revised their earnings estimate higher in the last 60 days for GSK, while the Zacks Consensus ...